Table 1.
Characteristics of patient participants.
| Patient characteristics | Overall (n = 47) | CN & usual care (n = 13) | CN + NF & usual care (n = 13) | CN & patient activation (n = 11) | CN + NF & patient activation (n = 10) |
|---|---|---|---|---|---|
| Age – mean (SD), years | 61.7 (13.6) | 62.5 (12.8) | 56.5 (15.2) | 67.3 (10.9) | 61.6 (14.6) |
| Age group – no. (%) | |||||
| Age 18-59 – no. (%) | 20 (42.6%) | 5 (38.5%) | 7 (53.8%) | 3 (27.3%) | 5 (50.0%) |
| Age 60-69 – no. (%) | 10 (21.3%) | 3 (23.1%) | 2 (15.4%) | 4 (36.4%) | 1 (10.0%) |
| Age 70-79 – no. (%) | 14 (29.8%) | 4 (30.8%) | 4 (30.8%) | 3 (27.8%) | 3 (30.0%) |
| Age 80+ – no. (%) | 3 (6.4%) | 1 (7.7%) | 0 (0.0%) | 1 (9.1%) | 1 (10.0%) |
| Gender – no. (%) | |||||
| Male sex | 30 (63.8%) | 6 (46.2%) | 10 (76.9%) | 7 (63.6%) | 7 (70.0%) |
| Race/ethnic group – no. (%) | |||||
| White, Not Hispanic | 39 (83.0%) | 11 (84.6%) | 9 (69.2%) | 11 (100.0%) | 8 (80.0%) |
| White, Hispanic | 1 (2.1%) | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) |
| Black, Not Hispanic | 3 (6.4%) | 1 (7.7%) | 1 (7.7%) | 0 (0.0%) | 1 (10.0%) |
| Asian, Not Hispanic | 2 (4.2%) | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 1 (10.0%) |
| Other, Not Hispanic | 2 (4.2%) | 1 (7.7%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) |
| Medical historya– no. (%) | |||||
| Atrial fibrillation/flutter | 18 (38.3%) | 5 (38.5%) | 6 (46.2%) | 3 (27.8%) | 4 (40.0%) |
| CAD | 19 (40.4%) | 7 (53.8%) | 3 (23.1%) | 3 (27.8%) | 6 (60.0%) |
| VTE | 9 (19.2%) | 2 (15.4%) | 2 (15.4%) | 3 (27.8%) | 2 (20.0%) |
| PAD | 11 (23.4%) | 4 (30.8%) | 1 (7.7%) | 4 (36.4%) | 2 (20.0%) |
| Valve replacement | 23 (48.9%) | 4 (30.8%) | 9 (69.2%) | 2 (18.2%) | 8 (80.0%) |
| Polycythemia vera | 1 (2.1%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Cerebrovascular disease | 7 (14.9%) | 2 (15.4%) | 1 (7.7%) | 3 (27.8%) | 1 (10.0%) |
| Indication for ongoing antiplatelet therapy – no. (%) | |||||
| None | 35 (74.5%) | 10 (76.9%) | 9 (69.2%) | 9 (81.8%) | 7 (70.0%) |
| CAD with intervention <12 months ago | 1 (2.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (10.0%) |
| On-X valve in aortic or pulmonary position | 6 (12.8%) | 1 (7.7%) | 3 (23.1%) | 0 (0.0%) | 2 (20.0%) |
| PAD with prior intervention | 3 (6.4%) | 0 (0.0%) | 1 (7.7%) | 2 (18.2%) | 0 (0.0%) |
| Refractory/extensive vascular disease | 2 (4.3%) | 2 (15.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Antiplatelet drugsa– no. (%) | |||||
| Aspirin | 43 (91.5%) | 11 (84.6%) | 13 (100.0%) | 10 (90.9%) | 9 (90.0%) |
| Clopidogrel | 3 (6.4%) | 1 (7.7%) | 0 (0.0%) | 1 (9.1%) | 1 (10.0%) |
| Prasugrel | 1 (2.1%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Ticagrelor | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Other drugsa– no. (%) | |||||
| Oral NSAIDs | 1 (2.1%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| SSRI | 5 (10.6%) | 3 (23.1%) | 1 (7.7%) | 0 (0.0%) | 1 (10.0%) |
| Aldosterone antagonists | 7 (14.9%) | 2 (15.4%) | 4 (30.8%) | 1 (9.1%) | 0 (0.0%) |
| Oral glucocorticoid | 7 (14.9%) | 4 (30.8%) | 0 (0.0%) | 1 (9.1%) | 2 (20.0%) |
| Specialty of target clinician – no. (%) | |||||
| PCP | 2 (4.3%) | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 1 (10.0%) |
| Cardiologist | 22 (46.8%) | 3 (23.1%) | 7 (53.8%) | 4 (36.4%) | 5 (50.0%) |
| Neurologist | 1 (2.1%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Surgeon | 22 (46.8%) | 9 (69.2%) | 5 (38.5%) | 7 (63.6%) | 4 (40.0%) |
CAD, coronary artery disease; CN, clinician notification; FN, nurse facilitation; NSAID, nonsteroidal anti-inflammatory drug; PAD, peripheral arterial disease; PCP, primary care provider; SSRI, selective serotonin reuptake inhibitor; VTE, venous thromboembolism.
aMedications and medical history were ascertained using the electronic medication and problem lists at the time of screening.